相关实验视频

Updated: Jul 1, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

在抵抗性灾难性抗脂综合征的情况下,eculizumab治疗和补充调节

Rachel Frederick^1,2, Luigi Zolio³, Evange Romas^3,4

¹Department of Nephrology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia rachfred99@gmail.com.

BMJ case reports

|March 5, 2024

概括

灾难性抗脂综合征 (CAPS) 是一种严重的疾病,导致广泛的血栓形成. 本案例研究强调eculizumab作为一种成功治疗标准疗法耐药的CAPS,并强调为未来管理进行基因测试.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
血液学血液学血液学

背景情况:

灾难性抗脂综合征 (CAPS) 是一种罕见的,危及生命的疾病,其特征是广泛的血栓形成和多器官衰竭.
不调节的补充激活在CAPS病变发生过程中起着至关重要的作用.
早期诊断和及时治疗对于改善CAPS的结果至关重要.

研究的目的:

报告一种对初始治疗有抗性的初级CAPS病例.
为了评估eculizumab在一种抗治疗的CAPS病例中的疗效.
强调基因测试在CAPS管理中的作用和未来的治疗影响.

主要方法:

一个患有初级CAPS的患者的病例报告.
对临床和实验室发现的审查.
评估对补充剂抑制剂eculizumab的反应.
包括遗传检测结果,并讨论其影响.

主要成果:

患者提出的临床和实验室发现与初级CAPS一致.
患者的病情对最初的标准治疗有抗性.
在这种耐火病例中,eculizumab治疗带来了积极的反应.
基因测试为潜在的治疗策略提供了洞察力.

结论:

埃奎利祖马布是治疗耐药CAPS的一个有前途的治疗选择.
补充抑制是管理严重CAPS的可行策略.
基因检测可能为CAPS患者提供个性化的治疗方法.

关键词:

急性功能衰竭急性功能衰竭是什么医疗管理医疗管理进行脏干预.腎臟醫學腎臟醫學

更多相关视频

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...